Background To evaluate the feasibility and security of complete remission (CR) of advanced
hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the …

Background & Aims Hepatocellular carcinoma (HCC) associated macrophages accelerate
tumor progression by growth factor release. Therefore, tumor-associated macrophages …

Introduction Sorafenib is the only drug approved by the Food and Drug Administration for
metastatic hepatocellular carcinoma (HCC). Triptolide, a diterpene triepoxide, exhibits …

Background Hepatocellular carcinoma (HCC) has a high incidence and mortality.
Radiotherapy and sorafenib have proven effective for HCC. Here, we investigated whether …

Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis
is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and …

Background Liver resection can be considered in some hepatocellular carcinoma (HCC)
patients who received sorafenib. The lack of clinical data about safety of resection after …

Case 1: A6 4-year-old man with hepatocellular carcinoma (HCC) had received local therapy
repeatedly for 20 years. In 2012, he underwent hepatic right lobectomy for recurrence of …

Background Intrahepatic cholangiocarcinoma (ICC) is rising in clinical importance due to the
increasing incidence worldwide, poor prognosis, and suboptimal response to therapies …

The multikinase-inhibition action of sorafenib provides strong rationales for its combination
use with radiotherapy. We investigated the in vitro and in vivo effect of sorafenib combined …

Background/Aim: Surgical resection remains the mainstay of treatment for hepatocellular
carcinoma (HCC). However, reducing the risk of postoperative recurrence is urgently …